Emerging Company Profile

<div class="articleWrapper"><div class="articleContent"><h1 class="text title">WindMIL: T cell source is key</h1><h2 class="title-bottom webtitle">WindMIL is harnessing marrow-derived T cells to develop cell therapies for cancer</h2><div class="byline">Elizabeth S. Eaton, Staff Writer</div><div class="date">February 26, 2020 9:26 PM GMT</div></div></div>

WindMIL Therapeutics Inc.

WindMIL: T cell source is key

WindMIL is harnessing marrow-derived T cells to develop cell therapies for cancer with greater persistence than TILs and broader reach than existing CAR Ts. 

WindMIL is harnessing marrow-derived T cells to develop cell therapies for cancer

Featured Analysis

Articles

Current Editions

Data Graphics

Podcasts & Webcasts

Special Reports & Presentations

White Papers

Analysis

BCIQ

Company Profiles

Product Profiles

Target Profiles

Financial Dashboards

BCIQ Data

All Events

China Healthcare Summit

Bio€quity Europe

Events

My Workspace

Company Overview

Management

Editorial & Research Team

Scientific Advisory Board

About BioCentury

Contact Us

Forgot Password

Trial

Subscribe

Advertising & Sponsorship

Career Opportunities

Customer Resource Center

Contact

Home